Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.

You may also be interested in...

Vfend Adds Candidiasis Indication; Label Notes QTc Effect Under 10 Msec

Revised Vfend labeling adding an esophageal candidiasis indication includes results of an FDA-requested study showing that the antifungal increases QTc by less than 10 milliseconds.

Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says

Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.

Fujisawa Micafungin Safety, Prophylatic Use Could Be Benefits Vs. Cancidas

Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts